The Contribution of Lipidomics in Ovarian Cancer Management: A Systematic Review.

diagnostic lipidomics ovarian cancer predictive biomarker prognostic

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
11 Sep 2023
Historique:
received: 29 07 2023
revised: 30 08 2023
accepted: 09 09 2023
medline: 28 9 2023
pubmed: 28 9 2023
entrez: 28 9 2023
Statut: epublish

Résumé

Lipidomics is a comprehensive study of all lipid components in living cells, serum, plasma, or tissues, with the aim of discovering diagnostic, prognostic, and predictive biomarkers for diseases such as malignant tumors. This systematic review evaluates studies, applying lipidomics to the diagnosis, prognosis, prediction, and differentiation of malignant and benign ovarian tumors. A literature search was performed in PubMed, Science Direct, and SciFinder. Only publications written in English after 2012 were included. Relevant citations were identified from the reference lists of primary included studies and were also included in our list. All studies included referred to the application of lipidomics in serum/plasma samples from human cases of OC, some of which also included tumor tissue samples. In some of the included studies, metabolome analysis was also performed, in which other metabolites were identified in addition to lipids. Qualitative data were assessed, and the risk of bias was determined using the ROBINS-I tool. A total of twenty-nine studies were included, fifteen of which applied non-targeted lipidomics, seven applied targeted lipidomics, and seven were reviews relevant to our objectives. Most studies focused on the potential application of lipidomics in the diagnosis of OC and showed that phospholipids and sphingolipids change most significantly during disease development. In conclusion, this systematic review highlights the potential contribution of lipids as biomarkers in OC management.

Identifiants

pubmed: 37762264
pii: ijms241813961
doi: 10.3390/ijms241813961
pmc: PMC10531399
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Metabolomics. 2016 Apr;12(4):
pubmed: 28819352
Talanta. 2016 Apr 1;150:88-96
pubmed: 26838385
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Oct 15;858(1-2):287-91
pubmed: 17766199
Life Sci. 2019 Apr 1;222:235-244
pubmed: 30853626
Gynecol Oncol. 2016 Jan;140(1):138-44
pubmed: 26521694
Clin Chim Acta. 2018 Jun;481:108-114
pubmed: 29481776
Sci Rep. 2021 Sep 13;11(1):18156
pubmed: 34518593
Nat Rev Drug Discov. 2005 Jul;4(7):594-610
pubmed: 16052242
Int J Mol Sci. 2013 Apr 10;14(4):7742-56
pubmed: 23574936
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Front Mol Biosci. 2022 Apr 14;9:770983
pubmed: 35495636
Cancers (Basel). 2019 Apr 11;11(4):
pubmed: 30979045
Oncotarget. 2017 Oct 26;8(61):102912-102922
pubmed: 29262533
J Pharm Biomed Anal. 2021 May 30;199:114048
pubmed: 33836461
Sci Rep. 2015 Nov 17;5:16351
pubmed: 26573008
Genome Biol. 2019 Jun 4;20(1):118
pubmed: 31164141
Int J Gynecol Cancer. 2021 May;31(5):754-774
pubmed: 33106272
PLoS One. 2012;7(10):e46846
pubmed: 23082132
Clin Transl Med. 2018 Jul 30;7(1):21
pubmed: 30058036
Toxins (Basel). 2021 Jun 30;13(7):
pubmed: 34209281
Cancer Drug Resist. 2018;1:181-197
pubmed: 31891125
Cancer Res. 2020 Mar 15;80(6):1357-1367
pubmed: 31969373
J Clin Pathol. 2013 Apr;66(4):273-81
pubmed: 23426716
Clin Chim Acta. 2012 May 18;413(9-10):861-8
pubmed: 22309680
Mol Biosyst. 2015 Feb;11(2):516-21
pubmed: 25424060
Cancers (Basel). 2019 Nov 26;11(12):
pubmed: 31769430
Int J Mol Sci. 2016 Nov 28;17(12):
pubmed: 27916803
Oncotarget. 2017 May 9;8(19):32134-32146
pubmed: 28389631
Sci Rep. 2016 Mar 21;6:23334
pubmed: 26996990
Metabolomics. 2017 Dec 1;14(1):7
pubmed: 30830321
Cell Signal. 2021 May;81:109949
pubmed: 33571664
Br J Cancer. 2018 Oct;119(7):847-854
pubmed: 30293997
Cancers (Basel). 2019 Dec 26;12(1):
pubmed: 31888002
Gynecol Oncol. 2017 Oct;147(1):139-144
pubmed: 28800942
Cancers (Basel). 2021 Apr 07;13(8):
pubmed: 33917079
Oncotarget. 2017 Jul 18;8(29):46834-46845
pubmed: 27564116

Auteurs

Vasiliki Tzelepi (V)

Department of Oncology, "Papageorgiou" General Hospital, 56429 Thessaloniki, Greece.

Helen Gika (H)

Biomic_Auth, Bioanalysis and Omics Lab, Centre for Interdisciplinary Research of Aristotle University of Thessaloniki, Innovation Area of Thessaloniki, 57001 Thermi, Greece.
Laboratory of Forensic Medicine and Toxicology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

Olga Begou (O)

Biomic_Auth, Bioanalysis and Omics Lab, Centre for Interdisciplinary Research of Aristotle University of Thessaloniki, Innovation Area of Thessaloniki, 57001 Thermi, Greece.
Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

Eleni Timotheadou (E)

Department of Oncology, "Papageorgiou" General Hospital, 56429 Thessaloniki, Greece.
Department of Medical Oncology, Aristotle University of Thessaloniki School of Medicine, 54124 Thessaloniki, Greece.

Classifications MeSH